Analysed BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading
21-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
13-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
10-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
09-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
07-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
06-04-2026
yahoo.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
02-04-2026
yahoo.com
BDRX: Initiating Coverage of Biodexa Pharmaceuticals; A Deep Value Oncology Platform Built Around Two High-Conviction Areas
30-03-2026
yahoo.com
What is the current price of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The current price of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is $4.
BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) since the previous trading day is $-0.33.
BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) since the previous trading day is -7.6212%.
What is the most recent average sentiment score for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The most recent average sentiment score for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is 42 out of 100.
What is the most recent average sentiment for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The most recent sentiment for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is .
SEC-8K** Filing Available For BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.